UNSPSC 51191577: Furosemide xantinol

This classification denotes a loop diuretic C13H21N5O4.C12H11ClN2O5S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Y1P3P1MD0G, chemically known as benzoic acid, 5-(aminosulfonyl)-4-chloro-2-((2-furanylmethyl)amino)-, compd. with 3,7-dihydro-7-(2-hydroxy-3-((2-hydroxyethyl)methylamino)propyl)-1,3-dimethyl-1h-purine-2,6-dione (1:1), but more generally known as furosemide xantinol, which bears US NIH Compound Identifier 71587213.

UNSPSC 51191577 Furosemide xantinol is a Commodity code covering pharmaceutical and chemical products for state and local government facilities. Recent opportunities posted under this code show a marked mismatch: the code nominally identifies a specific diuretic pharmaceutical, yet recent solicitations tag unrelated chemical supplies (sodium bisulfite for water treatment) and multi-source generic pharmaceutical programs under the same number. The most recent state and local procurement activity does not reflect furosemide-specific demand; instead, issuing bodies are using this code to source broader chemical commodities and generic medication inventories. State and local health departments, municipalities, and cooperative purchasing alliances are the primary issuing bodies, though the code's actual use does not align cleanly with its pharmaceutical product name.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, posted a Request for Proposal on January 20, 2026 (due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and over-the-counter products across participating state and local government facilities including Oregon. The City of Meriden, Connecticut posted an Invitation for Bid (B027-15) on July 8, 2026 (due July 29, 2026) for sodium bisulfite chemical supply to its Water Pollution Control Facility—a commodity wholly unrelated to the code's stated scope. The code shows limited recent activity specific to furosemide or comparable diuretic pharmaceuticals; procurement offices appear to be applying this code inconsistently across chemical and pharmaceutical categories. Firms targeting genuine pharmaceutical supply contracts under this code should expect cooperative purchasing vehicles (like MMCAP) and municipal health facility procurement rather than high-volume, narrowly defined pharmaceutical tenders.